Goal Reached Thanks to every supporter — we hit 100%!

Goal: 1000 CNY · Raised: 1000 CNY

100.0%
Buy Us a Coffee
Get alerts for future matching vulnerabilitiesLog in to subscribe
I. Basic Information for CVE-2023-29066
Vulnerability Information
Have questions about the vulnerability? See if Shenlong's analysis helps!
View Shenlong Deep Dive ↗

Although we use advanced large model technology, its output may still contain inaccurate or outdated information.Shenlong tries to ensure data accuracy, but please verify and judge based on the actual situation.

Vulnerability Title
Incorrect User Management
Source: NVD (National Vulnerability Database)
Vulnerability Description
The FACSChorus software does not properly assign data access privileges for operating system user accounts. A non-administrative OS account can modify information stored in the local application data folders.
Source: NVD (National Vulnerability Database)
CVSS Information
CVSS:3.1/AV:P/AC:L/PR:L/UI:N/S:U/C:N/I:L/A:L
Source: NVD (National Vulnerability Database)
Vulnerability Type
特权授予不正确
Source: NVD (National Vulnerability Database)
Vulnerability Title
BD FACSChorus 安全漏洞
Source: CNNVD (China National Vulnerability Database)
Vulnerability Description
BD FACSChorus是美国碧迪医疗（BD）公司的一款多通道流式细胞仪系统。 BD FACSChorus 存在安全漏洞，该漏洞源于软件未正确分配操作系统用户帐户的数据访问权限。
Source: CNNVD (China National Vulnerability Database)
CVSS Information
N/A
Source: CNNVD (China National Vulnerability Database)
Vulnerability Type
N/A
Source: CNNVD (China National Vulnerability Database)
Affected Products
VendorProductAffected VersionsCPESubscribe
Becton, Dickinson and Company (BD)FACSChorus 5.0 ~ 5.1 -
II. Public POCs for CVE-2023-29066
#POC DescriptionSource LinkShenlong Link
AI-Generated POCPremium

No public POC found.

Login to generate AI POC
III. Intelligence Information for CVE-2023-29066
Please Login to view more intelligence information
IV. Related Vulnerabilities
Same product: FACSChorus
Same vendor: Becton, Dickinson and Company (BD)
Same weakness: CWE-266
V. Comments for CVE-2023-29066

No comments yet

Leave a comment